Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevifoscorvir Sodium in Subjects With Moderate Hepatic Impairment and Healthy Subjects
NCT07342868Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevifoscorvir in hepatitis B (HBV) (2 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area under the concentration time curve at 4 days, Time to maximum plasma concentration at 4 days and 4 more. Started Jan 2026; status: completed.
02
Drugs
pevifoscorvir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07342868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342868.